Specify Company / Ticker to Get the Summary
Dividend History TBPH
Dividend Analytics TBPH
Max Ratio
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Theravance Biopharma Inc
TBPHTheravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes of medicines in the United States. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). The company's product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma. It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California. Address: 901 Gateway Boulevard, South San Francisco, CA, United States, 94080
Analytics
WallStreet Target Price
17.20 USDP/E Ratio
–Dividend Yield
–Financials TBPH
Results | 2019 | Dynamics |